Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Intangibles (2018 - 2024)

Akebia Therapeutics has reported Intangibles over the past 7 years, most recently at $9.0 million for Q3 2024.

  • Quarterly Intangibles fell 80.0% to $9.0 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $9.0 million through Sep 2024, down 80.0% year-over-year, with the annual reading at $36.0 million for FY2023, 50.0% down from the prior year.
  • Intangibles was $9.0 million for Q3 2024 at Akebia Therapeutics, down from $18.0 million in the prior quarter.
  • Over five years, Intangibles peaked at $282.1 million in Q1 2020 and troughed at $9.0 million in Q3 2024.
  • The 5-year median for Intangibles is $90.1 million (2022), against an average of $95.6 million.
  • Year-over-year, Intangibles decreased 11.43% in 2020 and then tumbled 80.0% in 2024.
  • A 5-year view of Intangibles shows it stood at $144.2 million in 2020, then fell by 25.0% to $108.1 million in 2021, then plummeted by 33.33% to $72.1 million in 2022, then crashed by 50.0% to $36.0 million in 2023, then tumbled by 75.0% to $9.0 million in 2024.
  • Per Business Quant, the three most recent readings for AKBA's Intangibles are $9.0 million (Q3 2024), $18.0 million (Q2 2024), and $27.0 million (Q1 2024).